|Bid||12.83 x 3100|
|Ask||13.19 x 2200|
|Day's Range||12.87 - 13.05|
|52 Week Range||12.87 - 17.07|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||29.55|
|Forward Dividend & Yield||0.73 (5.59%)|
|Ex-Dividend Date||Mar 30, 2022|
|1y Target Est||20.00|
TAK vs. ZTS: Which Stock Is the Better Value Option?
Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.
Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has authorized (Notice of Compliance) LIVTENCITY™ (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 Compared to conventionally used antivirals to treat post-transplant CMV, LIVTENCITY offers twice the efficacy1 and more than 10 times less toxicity.1*